#USA #New Orleans #28bio #Nexon™ Neurotechnology #Organoid Intelligence

28bio Introduces the Nexon™ Neurotechnology Platform

On June 9, 2025, 28bio, a pioneering neurotechnology firm, revealed the Nexon™ platform, a transformative innovation designed to enhance the understanding of human brain function. By merging tissue engineering, neural interfacing, and artificial intelligence, Nexon™ allows researchers to engineer human brains at scale, thereby replicating complex neurological activities including memory, learning, and cognition.

This groundbreaking platform is actively being utilized to refine the predictive capabilities associated with therapeutic efficacy and toxicity, significantly impacting the workflows of several global pharmaceutical companies. The demand for more reliable and relevant predictive models has intensified, especially in the context of neurological drug development which historically suffers from high failure rates due to the inadequate translatability of animal models.

The Role of Organoid Intelligence (OI)

One standout feature of the Nexon™ platform is its incorporation of Organoid Intelligence (OI). This innovative approach combines human brain organoids with brain-machine interfaces to model cognitive functions in vitro. The implications for drug development—particularly concerning neurodegenerative diseases such as Alzheimer’s—are profound, offering novel functional cognitive biomarkers that could radically change the landscape of therapeutic strategies.

Neurological drug development is currently facing some of the highest attrition rates in the pharmaceutical industry. However, the Nexon™ platform aims to address this issue by providing a more predictive framework that is reflective of human responses rather than relying solely on animal testing. Despite promising outcomes from preclinical studies, many treatments fail in clinical trials, underscoring the urgent need for improved models that can accurately forecast human outcomes.

Impacts on the Pharmaceutical Industry

Alif Saleh, the CEO of 28bio, emphasized the critical need for advanced solutions in neurological drug development: "We engineer human brains capable of elucidating the complexity of neurological processes and produce predictive data needed to change the trajectory of neurological drug development. Industry and regulators are urgently asking for solutions to develop better neurological drugs faster and cheaper." This sentiment echoes a broader industry-wide call for innovation as healthcare grapples with an escalating neurological health crisis.

Commitment to Ethical Development

28bio is not only focused on the scientific advancements offered by the Nexon™ platform but also emphasizes ethical standards in the development of brain organoid technology and engineered human cognition. By integrating rigorous ethical practices into their operational frameworks, 28bio aims to lead by example in an era where pharmaceutics and biotechnology must coincide responsibly with human health.

In conclusion, the introduction of the Nexon™ neurotechnology platform represents a major leap forward in drug development, offering a comprehensive tool that not only enhances our understanding of complex neurological processes but also raises the bar for therapeutic predictions and efficacy. As this platform continues to develop and more pharmaceutical entities adopt its capabilities, the prospects for combating neurological disorders will grow, ultimately benefiting patients worldwide.

For more details on 28bio and its innovative approaches, visit 28bio.com.